To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge
Status:
Withdrawn
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether Al38583 Ophthalmic Solution is safe and
effective in reducing tear eosinophil levels at 5-8 hours after Conjunctival Allergen
Challenge (CAC).